Sun Pharma-Takeda Alliance Set To Launch Vonoprazan Tablets In India

Sun Pharmaceutical Industries announced it has signed a non-exclusive patent licensing deal with Takeda Pharmaceutical Company to market Vonoprazan tablets in India under the brand name "Voltapraz." Vonoprazan, an innovative oral potassium-competitive acid blocker (PCAB), is used to treat reflux esophagitis and other acid-related disorders. The drug was originally discovered and developed by Takeda.

Under this agreement, Takeda has provided Sun Pharma with non-exclusive patent licensing rights to market Vonoprazan in India. GERD is widespread in India, affecting individuals regardless of their location, whether rural or urban. The prevalence of GERD in India varies between 5% and 28.5%. Factors contributing to GERD include age, body mass index (BMI), a non-vegetarian diet, consumption of tea/coffee, and the use of tobacco and alcohol.

In November 2023, the US FDA approved Vonoprazan for the healing and maintenance of healing of all grades of erosive esophagitis and relief from heartburn associated with erosive esophagitis. It was also approved, in combination with amoxicillin and clarithromycin or with amoxicillin alone, for the treatment of Helicobacter pylori (H. pylori) infection in adults.

The drug is approved in India for treatment of adults with Reflux esophagitis and other acid peptic disorders. "Sun Pharma is a leader in gastroenterology and we are excited to introduce Vonoprazan in India under non-exclusive patent licence from Takeda, said Kirti Ganorkar, CEO of India Business & Sun Pharma.

This collaboration showcases our dedication to gastrointestinal health by offering patients and healthcare providers an innovative solution for managing reflux esophagitis and other acid-related disorders. Sun Pharmaceuticals Industries, a prominent global pharmaceutical company, excels in both specialty and generic markets and is the leading pharmaceutical company in India.